Premium
Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer
Author(s) -
Leach T. N.,
Childress M. O.,
Greene S. N.,
Mohamed A. S.,
Moore G. E.,
Schrempp D. R.,
Lahrman S. R.,
Knapp D. W.
Publication year - 2012
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5829.2011.00280.x
Subject(s) - chlorambucil , medicine , chemotherapy , histiocytic sarcoma , complete remission , soft tissue sarcoma , cancer , gastroenterology , sarcoma , oncology , surgery , pathology , cyclophosphamide , immunohistochemistry
The purpose of this study was to assess the toxicoses and antitumor activity of metronomic chlorambucil at a dosage of 4 mg m −2 daily in dogs with naturally occurring cancer. Thirty‐six dogs were enrolled in the study. The protocol was well tolerated with no grade 3 or 4 toxicoses noted. Complete remission was achieved, and lasted over 35 weeks in three dogs (mast cell tumour, soft tissue sarcoma and thyroid carcinoma). Partial remission was noted in 1 dog with histiocytic sarcoma (39 weeks duration) for an overall remission rate of 11% (4 of 36). Stable disease was noted in 17 dogs (47%) with various other cancers. The median progression‐free interval was 61 days, and the median survival time was 153 days. Chlorambucil given in a metronomic protocol showed antitumor activity in dogs with a variety of naturally occurring cancers.